HRA Pharma, SA acquired Lysodren Drug ownership right from Bristol-Myers Squibb Company (NYSE:BMY) on March 14, 2018. Under the transaction, HRA Pharma acquired development, manufacture and commercialization rights to the medicine in all markets, including Europe, the United States, Canada, Brazil and South Korea, as well as a named patient basis distribution in a number of additional geographies. Renaud Bonnet of Jones Day acted as legal advisor for HRA Pharma. HRA Pharma, SA completed the acquisition of Lysodren Drug ownership right from Bristol-Myers Squibb Company (NYSE:BMY) on March 14, 2018.